ADVERTISEMENT

Brazil struggles to vaccinate as COVID toll spirals

Published May 16, 2021 12:18 pm

Four months into a COVID-19 vaccination campaign marred by shortages and delays, hard-hit Brazil is still struggling to find enough doses, as political and diplomatic blunders prolong its pandemic nightmare.

Around 33 million people -- 15 percent of the population -- have received at least one vaccine dose in Brazil, a proportion still too small to have a substantial impact on the virus' spread.

Targeted by a Senate inquiry over its handling of the pandemic, President Jair Bolsonaro's government is facing criticism for failing to secure more vaccines, including its refusal of offers to purchase millions of doses and diplomatic tension with China that may be slowing the import of vaccine ingredients.

"We don't have enough doses right now to vaccinate as fast as we should," said Margareth Dalcolmo, a pulmonologist and researcher at leading public health institute Fiocruz.

"We ought to be vaccinating younger people already, especially given that younger demographic groups are currently driving transmission," she told AFP.

But first, Brazil still has to vaccinate 80 million people from high-priority groups, including the elderly, indigenous people and health workers.

Vaccine doses meanwhile continue to arrive in a trickle -- although the government maintains it will be able to vaccinate all adults by the end of the year.

Brazil has lost more lives to Covid-19 than any country except the United States -- more than 430,000 -- and has one of the highest death tolls per capita in the world.

Though the current wave has eased somewhat since April, the virus is still killing a staggeringly high number of people in the country -- nearly 2,000 a day.

- Rejected deal -

Despite its huge size, the South American country is known for executing turbo-charged vaccination campaigns.

In 2010, Brazil vaccinated more than 80 million people against H1N1 -- the swine flu virus -- in less than three months.

"We need to be vaccinating two million people a day," said Dalcolmo.

As it stands, Brazil has rarely managed more than one million COVID-19 shots a day.

"We've gotten better since the start of the year, but we're still a long way from where we need to be," said Joao Viola, president of the Brazilian Immunological Society's scientific committee.

Brazil started out using two vaccines, Oxford/AstraZeneca's and Chinese-developed CoronaVac, both of which it has licenses to produce locally.

The drive got a boost last month with the arrival of the Pfizer vaccine. But only about two million of the 100 million doses Brazil has ordered have been delivered so far.

All three shots require two doses.

Brazil could have secured more Pfizer doses faster, but Bolsonaro's government refused an offer last August to purchase more than 70 million of them.

The far-right president, who has persistently snubbed expert advice on handling the pandemic, joked that the vaccine could "turn you into an alligator" -- only to change course months later and allow a deal with the US pharmaceutical giant.

"Worldwide demand for vaccines is very high, so those who were slow to sign deals are receiving their orders later," said Viola.

- Diplomatic tension -

Bolsonaro, whose government often has strained relations with China, also refused to purchase CoronaVac, calling it the vaccine from "that other country."

But a political opponent, Joao Doria, governor of Brazil's most populous state, Sao Paulo, pursued a deal for CoronaVac anyway.

The vaccine now accounts for more than 70 percent of the doses administered in Brazil.

However, the public health center manufacturing it in Brazil, the Butantan Institute, announced Friday it would have to halt production because it had run out of the active ingredient, which has to be imported from China.

Brazil is due to start producing the active ingredient for CoronaVac itself, but only in September.

The Butantan Institute said "diplomatic problems" could prevent it from delivering new doses in June.

Last week, Bolsonaro provoked China by saying it may have created the novel coronavirus in a lab to wage "germ warfare."

"There are 10,000 liters (of active ingredient for CoronaVac) ready, just waiting for the Chinese government to authorize shipment," said Doria.

"But every time someone here makes a disparaging remark about China, that clearly makes it more difficult."

Related Tags

health brazil virus
ADVERTISEMENT
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1561_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1562_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1563_widget.title }}

{{ articles_filter_1564_widget.title }}

.mb-article-details { position: relative; } .mb-article-details .article-body-preview, .mb-article-details .article-body-summary{ font-size: 17px; line-height: 30px; font-family: "Libre Caslon Text", serif; color: #000; } .mb-article-details .article-body-preview iframe , .mb-article-details .article-body-summary iframe{ width: 100%; margin: auto; } .read-more-background { background: linear-gradient(180deg, color(display-p3 1.000 1.000 1.000 / 0) 13.75%, color(display-p3 1.000 1.000 1.000 / 0.8) 30.79%, color(display-p3 1.000 1.000 1.000) 72.5%); position: absolute; height: 200px; width: 100%; bottom: 0; display: flex; justify-content: center; align-items: center; padding: 0; } .read-more-background a{ color: #000; } .read-more-btn { padding: 17px 45px; font-family: Inter; font-weight: 700; font-size: 18px; line-height: 16px; text-align: center; vertical-align: middle; border: 1px solid black; background-color: white; } .hidden { display: none; }
function initializeAllSwipers() { // Get all hidden inputs with cms_article_id document.querySelectorAll('[id^="cms_article_id_"]').forEach(function (input) { const cmsArticleId = input.value; const articleSelector = '#article-' + cmsArticleId + ' .body_images'; const swiperElement = document.querySelector(articleSelector); if (swiperElement && !swiperElement.classList.contains('swiper-initialized')) { new Swiper(articleSelector, { loop: true, pagination: false, navigation: { nextEl: '#article-' + cmsArticleId + ' .swiper-button-next', prevEl: '#article-' + cmsArticleId + ' .swiper-button-prev', }, }); } }); } setTimeout(initializeAllSwipers, 3000); const intersectionObserver = new IntersectionObserver( (entries) => { entries.forEach((entry) => { if (entry.isIntersecting) { const newUrl = entry.target.getAttribute("data-url"); if (newUrl) { history.pushState(null, null, newUrl); let article = entry.target; // Extract metadata const author = article.querySelector('.author-section').textContent.replace('By', '').trim(); const section = article.querySelector('.section-info ').textContent.replace(' ', ' '); const title = article.querySelector('.article-title h1').textContent; // Parse URL for Chartbeat path format const parsedUrl = new URL(newUrl, window.location.origin); const cleanUrl = parsedUrl.host + parsedUrl.pathname; // Update Chartbeat configuration if (typeof window._sf_async_config !== 'undefined') { window._sf_async_config.path = cleanUrl; window._sf_async_config.sections = section; window._sf_async_config.authors = author; } // Track virtual page view with Chartbeat if (typeof pSUPERFLY !== 'undefined' && typeof pSUPERFLY.virtualPage === 'function') { try { pSUPERFLY.virtualPage({ path: cleanUrl, title: title, sections: section, authors: author }); } catch (error) { console.error('ping error', error); } } // Optional: Update document title if (title && title !== document.title) { document.title = title; } } } }); }, { threshold: 0.1 } ); function showArticleBody(button) { const article = button.closest("article"); const summary = article.querySelector(".article-body-summary"); const body = article.querySelector(".article-body-preview"); const readMoreSection = article.querySelector(".read-more-background"); // Hide summary and read-more section summary.style.display = "none"; readMoreSection.style.display = "none"; // Show the full article body body.classList.remove("hidden"); } document.addEventListener("DOMContentLoaded", () => { let loadCount = 0; // Track how many times articles are loaded const offset = [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]; // Offset values const currentUrl = window.location.pathname.substring(1); let isLoading = false; // Prevent multiple calls if (!currentUrl) { console.log("Current URL is invalid."); return; } const sentinel = document.getElementById("load-more-sentinel"); if (!sentinel) { console.log("Sentinel element not found."); return; } function isSentinelVisible() { const rect = sentinel.getBoundingClientRect(); return ( rect.top < window.innerHeight && rect.bottom >= 0 ); } function onScroll() { if (isLoading) return; if (isSentinelVisible()) { if (loadCount >= offset.length) { console.log("Maximum load attempts reached."); window.removeEventListener("scroll", onScroll); return; } isLoading = true; const currentOffset = offset[loadCount]; window.loadMoreItems().then(() => { let article = document.querySelector('#widget_1690 > div:nth-last-of-type(2) article'); intersectionObserver.observe(article) loadCount++; }).catch(error => { console.error("Error loading more items:", error); }).finally(() => { isLoading = false; }); } } window.addEventListener("scroll", onScroll); });

Sign up by email to receive news.